Sarepta Therapeutics, Inc. (SRPT)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 109.26 |
| Open | 109.30 |
| Bid | 105.30 x 800 |
| Ask | 108.99 x 1300 |
| Day's range | 108.61 - 110.96 |
| 52-week range | 61.28 - 113.60 |
| Volume | |
| Avg. volume | 926,570 |
| Market cap | 9.545B |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust
Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.
- Motley Fool
Sarepta Therapeutics (SRPT) Q2 2022 Earnings Call Transcript
Good day, ladies and gentlemen, thank you for standing by, and welcome to Sarepta Therapeutics second quarter 2022 earnings conference call. Actual results could materially differ from these forward-looking statements, and any such risks can materially and adversely affect the business, the results of operations, and trading prices for Sarepta's common stock.
- Zacks
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2022 Yahoo. All rights reserved.
